Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.70 |
| ▸ | MEN1 | O00255 | 10/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.62 |
| ▸ | MYC | P01106 | 6/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | MAX | P61244 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.55 |
| ▸ | ARNT | P27540 | 3/20 | 0.55 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3702011 | 0.82 | IDO1 (0.76) | IDO1MEN1KMT2AMYCNPC1 | |
| SCHEMBL300424 | 0.82 | IDO1 (1.00) | IDO1MEN1KMT2AMYCNPC1 | |
| SCHEMBL14933668 | 0.82 | TNF (0.66) | IDO1MEN1KMT2AMYCNPC1 | |
| SCHEMBL9099682 | 0.82 | IDO1 (0.64) | IDO1MEN1KMT2AMYCNPC1 | |
| SCHEMBL300460 | 0.81 | KMT2A (0.73) | IDO1MEN1KMT2AMYCNPC1 | |
| SCHEMBL14933670 | 0.81 | IDO1 (0.69) | IDO1MEN1KMT2AMYCNPC1 | |
| SCHEMBL12218579 | 0.81 | ARNT (0.70) | IDO1MEN1KMT2AMYCNPC1 | |
| SCHEMBL17934623 | 0.79 | IDO1 (0.74) | IDO1MEN1KMT2AMYCNPC1 | |
| SCHEMBL17927389 | 0.79 | IDO1 (0.67) | IDO1MEN1KMT2AMYCNPC1 | |
| SCHEMBL6834810 | 0.78 | IDO1 (0.78) | IDO1MEN1KMT2AMYCNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096554-B2 | Drugs for inhibiting p38 and uses thereof | Universidad Autónoma de Madrid (ES) | 2015-08-04 | — | — | US | disclosed |
| US-9096554-B2 | Drugs for inhibiting p38 and uses thereof | Universidad Autónoma de Madrid (ES) | 2015-08-04 | — | — | US | disclosed |
| US-20140296308-A1 | DRUGS FOR INHIBITING P38 AND USES THEREOF | Universidad Autónoma de Madrid (ES) | 2014-10-02 | — | — | US | disclosed |
| US-20140296308-A1 | DRUGS FOR INHIBITING P38 AND USES THEREOF | Universidad Autónoma de Madrid (ES) | 2014-10-02 | — | — | US | disclosed |
| WO-2013064714-A1 | DRUGS FOR INHIBITING P38 AND USES THEREOF | Universidad Autónoma de Madrid (ES) | 2013-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296308-A1 | DRUGS FOR INHIBITING P38 AND USES THEREOF | MAPK1, MAPK4, MAPK8 | IDO1 1545/4885MEN1 3940/4885KMT2A 3069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.